Report Thumbnail
Product Code IW091281444HB9
Published Date 2021/8/2
English210 PagesGlobal

GLOBAL COUGH SYRUP MARKET FORECAST 2021-2028Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code IW091281444HB9◆The Aug 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2021/8/2
English 210 PagesGlobal

GLOBAL COUGH SYRUP MARKET FORECAST 2021-2028Pharmaceutical_LifeSciense Market



Abstract


Summary

KEY FINDINGS The global cough syrup market is anticipated to develop with a CAGR of 2.87% over the forecasting years of 2021 to 2028. The market growth is mainly ascribed to chief factors such as the increasing geriatric population as well as the surging incidence of chronic respiratory conditions. MARKET INSIGHTS Coughing is primarily caused by respiratory problems like asthma, chronic obstructive pulmonary disease, chronic lung infections, pulmonary disease, and lung cancer. Cough syrups suppress and loosen mucus present in the airways, clear the congestion and make breathing easier. They also help with allergic symptoms such as runny nose, throat irritation, watery eyes, and sneezing. Besides, certain combination cough syrups relieve coughs caused due to bronchitis, common cold, and numerous other breathing illnesses. With fast-paced urbanization, in addition to the rising energy consumption globally, the level of indoor and outdoor air pollution generated from industrial and motor vehicle emissions continues to augment rapidly. As a result, there is a considerable rise in the prevalence of respiratory symptoms, including coughing, decreased pulmonary function, and wheezing. Moreover, exposure to particulate matter, nitrogen dioxide, ozone, and tobacco smoke has an adverse influence on the development of respiratory conditions, significantly associated with wheeze and cough. The main disease concerns are asthma, respiratory tract infections, rhinosinusitis, and chronic obstructive pulmonary disease. REGIONAL INSIGHTS The global cough syrup market growth is evaluated through the analysis of North America, Europe, the Asia-Pacific, and the Rest of World. The Asia-Pacific is set to lead as well as dominate the global market owing to factors such as the increasing incidence of lung-related problems, the influence of various environmental, economic, and social aspects on the region’s respiratory health, and the growing rates of air pollution. COMPETITIVE INSIGHTS Companies with larger portfolios and undifferentiated products create extensive competition within the global cough syrup market. Furthermore, major firms possess a strong geographical presence worldwide and also provide a diversified product range. Hence, the competitive rivalry is set to be high in the global market. Key enterprises operating in the market are Proctor & Gamble Co, GlaxoSmithKline PLC, Johnson & Johnson, etc. Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents

  • 1 RESEARCH SCOPE & METHODOLOGY

    • 1.1 STUDY OBJECTIVES
    • 1.2 SCOPE OF STUDY
    • 1.3 METHODOLOGY
    • 1.4 ASSUMPTIONS & LIMITATIONS
  • 2 EXECUTIVE SUMMARY

    • 2.1 MARKET SIZE & ESTIMATES
    • 2.2 MARKET OVERVIEW
  • 3 MARKET DYNAMICS

    • 3.1 KEY DRIVERS
      • 3.1.1 RISING GERIATRIC POPULATION
      • 3.1.2 INCREASE IN CHRONIC RESPIRATORY DISEASES
    • 3.2 KEY RESTRAINTS
      • 3.2.1 OVERDOSE RISKS ASSOCIATED WITH COUGH SYRUP
      • 3.2.2 GOVERNMENT REGULATIONS AND RESTRICTIONS
  • 4 KEY ANALYTICS

    • 4.1 IMPACT OF COVID-19 ON COUGH SYRUP MARKET
    • 4.2 KEY MARKET TRENDS
    • 4.3 PORTER’S FIVE FORCES ANALYSIS
      • 4.3.1 BUYERS POWER
      • 4.3.2 SUPPLIERS POWER
      • 4.3.3 SUBSTITUTION
      • 4.3.4 NEW ENTRANTS
      • 4.3.5 INDUSTRY RIVALRY
    • 4.4 OPPORTUNITY MATRIX
    • 4.5 VENDOR LANDSCAPE
  • 5 MARKET BY PRODUCT TYPE

    • 5.1 COUGH SUPPRESSANTS/ANTITUSSIVES
    • 5.2 COMBINATION MEDICATIONS
    • 5.3 EXPECTORANTS
  • 6 MARKET BY AGE GROUP

    • 6.1 ADULT
    • 6.2 PEDIATRIC
  • 7 MARKET BY DISTRIBUTION CHANNELS

    • 7.1 RETAIL PHARMACY
    • 7.2 HOSPITAL PHARMACY
    • 7.3 ONLINE PHARMACY
  • 8 GEOGRAPHICAL ANALYSIS

    • 8.1 NORTH AMERICA
      • 8.1.1 MARKET SIZE & ESTIMATES
      • 8.1.2 KEY DRIVERS
      • 8.1.3 KEY CHALLENGES
      • 8.1.4 KEY PLAYERS
      • 8.1.5 COUNTRY ANALYSIS
        • 8.1.5.1 UNITED STATES
        • 8.1.5.2 CANADA
    • 8.2 EUROPE
      • 8.2.1 MARKET SIZE & ESTIMATES
      • 8.2.2 KEY DRIVERS
      • 8.2.3 KEY CHALLENGES
      • 8.2.4 KEY PLAYERS
      • 8.2.5 COUNTRY ANALYSIS
        • 8.2.5.1 UNITED KINGDOM
        • 8.2.5.2 GERMANY
        • 8.2.5.3 FRANCE
        • 8.2.5.4 ITALY
        • 8.2.5.5 RUSSIA
        • 8.2.5.6 BELGIUM
        • 8.2.5.7 POLAND
        • 8.2.5.8 REST OF EUROPE
    • 8.3 ASIA-PACIFIC
      • 8.3.1 MARKET SIZE & ESTIMATES
      • 8.3.2 KEY DRIVERS
      • 8.3.3 KEY CHALLENGES
      • 8.3.4 KEY PLAYERS
      • 8.3.5 COUNTRY ANALYSIS
        • 8.3.5.1 CHINA
        • 8.3.5.2 JAPAN
        • 8.3.5.3 INDIA
        • 8.3.5.4 SOUTH KOREA
        • 8.3.5.5 INDONESIA
        • 8.3.5.6 THAILAND
        • 8.3.5.7 VIETNAM
        • 8.3.5.8 AUSTRALIA & NEW ZEALAND
        • 8.3.5.9 REST OF ASIA-PACIFIC
    • 8.4 REST OF WORLD
      • 8.4.1 MARKET SIZE & ESTIMATES
      • 8.4.2 KEY DRIVERS
      • 8.4.3 KEY CHALLENGES
      • 8.4.4 REGIONAL ANALYSIS
        • 8.4.4.1 LATIN AMERICA
        • 8.4.4.2 MIDDLE EAST & AFRICA
  • 9 COMPETITIVE LANDSCAPE

    • 9.1 KEY STRATEGIC DEVELOPMENTS
      • 9.1.1 MERGERS & ACQUISITIONS
      • 9.1.2 PARTNERSHIPS & AGREEMENTS
    • 9.2 COMPANY PROFILES
      • 9.2.1 ABBOTT LABORATORIES
      • 9.2.2 ACELLA PHARMACEUTICALS LLC
      • 9.2.3 ASTRAZENECA PLC
      • 9.2.4 CIPLA LIMITED
      • 9.2.5 DABUR INDIA LTD
      • 9.2.6 GLAXOSMITHKLINE PLC
      • 9.2.7 GLENMARK PHARMACEUTICAL LIMITED
      • 9.2.8 JOHNSON & JOHNSON
      • 9.2.9 MERCK KGAA
      • 9.2.10 NOVARTIS INTERNATIONAL AG
      • 9.2.11 PFIZER INC
      • 9.2.12 PROCTOR & GAMBLE CO (P&G)
      • 9.2.13 RECKITT BENCKISER GROUP PLC
      • 9.2.14 SANOFI SA
      • 9.2.15 THE HIMALAYA DRUG COMPANY
USD 2,900 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.